4 February 2025, Mumbai: Alembic Pharmaceuticals Limited reported its consolidated financial results for the third quarter ended 31st December, 2024.
Financial Highlights
- Net Sales increased by 4% to Rs.1693 Crores.
- EBITDA up 1% to Rs. 271 Crores
- EBITDA Margin at 16% of Sales
- Net Profit at Rs.138 Crores
Mr. Shaunak Amin, MD, Alembic Pharmaceuticals Limited said. “In the current quarter, we faced market headwinds in the acute segment. However, other key therapies in our specialty business continued to outpace the market growth. To strengthen field force efficiency, we have enhanced Automation and AI, to upscale execution. This Transition has partly impacted quarter growth. We are confident to show a robust growth trajectory going forward. The US Business posted significant volume growth and the Ex-US markets continued to expand steadily. API Business is still under significant pricing pressure.”
India Branded Business
- India Branded Business grew 3% to Rs. 614 crores for the quarter.
- Animal Health business grew 22% for the quarter with basket of strong brands driving outperformance.
- Specialty therapies recorded growth of 6%.
- 3 launches during the quarter. New launches continue to do well along with promising future launches across key segments.
International Business
- US Generics grew 10% to Rs. 521 Crores for the quarter.
- 2 Launches in the US market during the quarter.
- Ex-US International Generics grew 10% to Rs. 299 Crores for the quarter.
- 7 ANDA approvals received during the quarter, 219 Cumulative ANDA approvals.
API Business
Particulars | Q3 FY25 | Q3 FY24 | % Change | 9M FY25 | 9M FY24 | % Change |
Formulation | ||||||
India | 614 | 596 | 3% | 1795 | 1697 | 6% |
USA
Ex- US |
521
299 |
474
272 |
10%
10% |
1449
868 |
1308
790 |
11%
10% |
API | 259 | 289 | (10%) | 791 | 916 | (14%) |
Total | 1693 | 1631 | 4% | 4902 | 4712 | 4% |